Raltegravir 25mg chewable tablets
Requires a prescription from a doctor or prescriber
Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Raltegravir
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Raltegravir
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Raltegravir on the MHRA register
Isentress 25mg chewable tablets
WHO defined daily dose (DDD)
800 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(1)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 3 · Randomised trials: 24 · 2007–2026
Showing the 50 most relevant studies, sorted by most relevant.
Jeffrey L. Lennox, Edwin DeJesus, Adriano Lazzarin, et al.
The Lancet, 2009
- Emtricitabine
- Tenofovir
- Raltegravir Potassium
Beatriz Grinsztejn, Bach-Yen Nguyen, Christine Katlama, et al.
The Lancet, 2007
- Raltegravir Potassium
- Atazanavir Sulfate
- Oligopeptides
François Raffi, Hans Jaeger, Eugenia Quirós-Roldán, et al.
The Lancet Infectious Diseases, 2013
- Tenofovir
- Raltegravir Potassium
- Dolutegravir
Joseph J. Eron, Benjamin Young, David A. Cooper, et al.
The Lancet, 2010
- Raltegravir Potassium
- Cholesterol, LDL
- Pyrimidinones
Rajesh T. Gandhi, Lu Zheng, Ronald J. Bosch, et al.
PLoS Medicine, 2010
- Raltegravir Potassium
- Pyrrolidinones
- Viremia
Hiroyu Hatano, Timothy L. Hayes, Viktor Dahl, et al.
The Journal of Infectious Diseases, 2011
- Raltegravir Potassium
- HLA-DR Antigens
- Membrane Glycoproteins
Joseph J. Eron, Jürgen K. Rockstroh, Jacques Reynes, et al.
The Lancet Infectious Diseases, 2011
- HIV-1
- Raltegravir Potassium
- Pyrrolidinones
Hiroyu Hatano, Matthew C. Strain, Rebecca Scherzer, et al.
The Journal of Infectious Diseases, 2013
- Raltegravir Potassium
- Fibrin Fibrinogen Degradation Products
- Pyrrolidinones
François Raffi, Abdel G. Babiker, Laura Richert, et al.
The Lancet, 2014
- Emtricitabine
- Tenofovir
- Raltegravir Potassium
Zhang Y, Wu W, Yang M, et al.
2025
- Pregnancy Complications, Infectious
- HIV Infections
- HIV Integrase Inhibitors
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
90 found
Half-life
9 hours
Mechanism
Raltegravir inhibits HIV integrase to prevent the viral genome being incorporated into the human genome.
Food interactions
1 warning
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
Half-life
9 hours
Protein binding
83%
Volume of distribution
83%
Metabolism
Elimination
Clearance
9%
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 240 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC J05AR16
ATC J05AJ01
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Raltegravir
Additional database identifiers
Drugs Product Database (DPD)
20173
ChemSpider
16445111
BindingDB
25351
PDB
RLT
ZINC
ZINC000013831130
UniProt Accession
Q7ZJM1_HV1
GenBank Gene Database
M15654
GenBank Protein Database
326388
UniProt Accession
POL_HV1B1
HUGO Gene Nomenclature Committee (HGNC)
HGNC:12530
GeneCards
UGT1A1
GenBank Gene Database
M57899
GenBank Protein Database
184473
Guide to Pharmacology
2990
UniProt Accession
UD11_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q421552), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.